• Arcutis posted Q2 net income of USD 15 million, swinging from a net loss, as net product revenue rose 59% year over year to USD 129.9 million.
• Operating income improved to USD 16.43 million from an operating loss, while SG&A climbed to USD 82.14 million on higher personnel costs.
• R&D edged up to USD 20.36 million, while operating cash flow stayed positive at USD 12.6 million.
• 2026 net product sales guidance was raised to USD 525 million-USD 540 million.
• ZORYVE cream 0.3% gained FDA clearance for plaque psoriasis down to age 2; FDA set Feb. 23, 2027 action date for infant atopic dermatitis sNDA.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051600PRIMZONEFULLFEED9804531) on August 05, 2026, and is solely responsible for the information contained therein.